Imagion Biosystems Limited
Imagion Biosystems Limited (IBXXF) Revenue
Annual & quarterly revenue history · segment & region breakdown
IBXXF · revenue · updated Jun 15, 2026
Core revenue metrics
Trailing 12 monthsImagion Biosystems Limited trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -100.00% |
| 2024-12-31 | $0.00B | -$0.00B | -46.38% |
| 2023-12-31 | $0.00B | +$0.00B | +61.87% |
| 2022-12-31 | $0.00B | +$0.00B | +7.54% |
| 2021-12-31 | $0.00B | +$0.00B | +1288.10% |
| 2020-12-31 | $0.00B | -$0.00B | -49.93% |
| 2019-12-31 | $0.00B | +$0.00B | +114.57% |
| 2018-12-31 | $0.00B | +$0.00B | +852.53% |
| 2017-12-31 | $0.00B | +$0.00B | +167416.67% |
| 2016-12-31 | $0.00B | -$0.00B | -99.78% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Imagion Biosystems Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Imagion Biosystems Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in AUD.
Data sourced from Imagion Biosystems Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IBXXF revenue · 4 questionsIBXXF's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Imagion Biosystems Limited SEC filings · GAAP · Imagion Biosystems Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026